Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-23-037243)

NAMES OF REPORTING PERSONS

Revelation Alpine, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☑

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

Accession Number:: 0001193125-23-037243
Form Type:: 13G Filing
Publication Date:: 2023-02-13 19:00:00

Filed By:: Revelation Alpine, Llc
Company:: Singular Genomics Systems Inc.
Filing Date:: 2023-02-14
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Sole Voting Power	Sole Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Revelation Alpine	1,184,497	1,184,497	1,184,497	1.7%
Revelation Alpine GP	1,184,497	1,184,497	1,184,497	1.7%
Revelation Healthcare Fund II	231,349	231,349	231,349	0.3%
Revelation Healthcare Fund II GP	231,349	231,349	231,349	0.3%
Revelation Healthcare Fund II GP	231,349	231,349	231,349	0.3%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Singular Genomics Systems, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

82933R100

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☑ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 82933R100		SCHEDULE 13G		Page 2 of 9 Pages

(1)	The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


CUSIP No. 82933R100		SCHEDULE 13G		Page 3 of 9 Pages

(1)	The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


CUSIP No. 82933R100		SCHEDULE 13G		Page 4 of 9 Pages

(1)	The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


CUSIP No. 82933R100		SCHEDULE 13G		Page 5 of 9 Pages

(1)	The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


CUSIP No. 82933R100		SCHEDULE 13G		Page 6 of 9 Pages

(1)	The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


CUSIP No. 82933R100		SCHEDULE 13G		Page 7 of 9 Pages


Item 1.			Issuer

	(a)		Name of Issuer:
			Singular Genomics Systems, Inc. (the Issuer)

	(b)		Address of Issuers Principal Executive Offices:
			3010 Science Park Road San Diego, CA 92121

Item 2.			Filing Person

	(a) (c)		Name of Persons Filing; Address; Citizenship:

			(i) Revelation Alpine, LLC, a Delaware limited liability company (Alpine). (ii) Revelation Alpine GP, LLC, a Delaware limited liability company (Alpine GP). (iii) Revelation Healthcare Fund II, L.P., a Delaware limited partnership (Healthcare Fund II). (iv) Revelation Healthcare Fund II GP, L.P., a Delaware limited partnership (Healthcare Fund II GP LP). (v) Revelation Healthcare Fund II GP, LLC, a Delaware limited liability company (Healthcare Fund II GP LLC). The address of the principal business office of each of the Reporting Persons is 300 Turney Street, Sausalito, CA 94965.

	(d)		Title of Class of Securities:

			Common Stock, par value $0.0001 per share

	(e)		CUSIP Number: 82933R100

Item 3.	If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

	(a)	☐	Broker or dealer registered under Section 15 of the Act;

	(b)	☐	Bank as defined in Section 3(a)(6) of the Act;

	(c)	☐	Insurance company as defined in Section 3(a)(19) of the Act;

	(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940;

	(e)	☐	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

	(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

	(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

	(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

	(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

	(j)	☐	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

	(k)	☐	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

		If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


CUSIP No. 82933R100		SCHEDULE 13G		Page 8 of 9 Pages

Item 4.

Ownership.

(a) and (b)

Amount beneficially owned:

(i)

Alpine directly owns 1,184,497 shares of Common Stock, which represents approximately 1.7% of the
outstanding shares of Common Stock. Alpine GP, as general partner of Alpine, may be deemed to
beneficially own the shares of Common Stock held directly by Alpine.

(ii)

Healthcare Fund II directly owns 231,349 shares of Common Stock, which represents approximately
0.3% of the outstanding shares of Common Stock. Healthcare Fund II GP LP, as general partner of
Healthcare Fund II, and Healthcare Fund II GP LLC, as general partner of Healthcare Fund II GP LP,
may each be deemed to beneficially own the shares of Common Stock held directly by Healthcare Fund
II.



	Number of Shares of Common Stock
Reporting Person	(i)		(ii)		(iii)		(iv)
Alpine		1,184,497		0		1,184,497		0
Alpine GP		1,184,497		0		1,184,497		0
Healthcare Fund II		231,349		0		231,349		0
Healthcare Fund II GP LP		231,349		0		231,349		0
Healthcare Fund II GP LLC		231,349		0		231,349		0

(i) Sole power to vote or direct the vote
(ii) Shared power to vote or to direct the vote
(iii) Sole power to dispose or to direct the disposition of
(iv) Shared power to dispose or to direct the disposition of

The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022,
as reported in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on
November 7, 2022.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: ☑

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

Not applicable.


CUSIP No. 82933R100		SCHEDULE 13G		Page 9 of 9 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2023


REVELATION ALPINE, LLC

By: Revelation Alpine GP, LLC
Its: General Partner

By:		/s/ Michael Boggs
Name:		Michael Boggs
Title:		Managing Member

REVELATION ALPINE GP, LLC

By:		/s/ Michael Boggs
Name:		Michael Boggs
Title:		Managing Member

REVELATION HEALTHCARE FUND II, L.P.

By: Revelation Healthcare Fund II GP, L.P.
Its: General Partner

By: Revelation Healthcare Fund II GP, LLC
Its: General Partner

By:		/s/ Michael Boggs
Name:		Michael Boggs
Title:		Managing Member

REVELATION HEALTHCARE FUND II GP, L.P.

By: Revelation Healthcare Fund II GP, LLC
Its: General Partner

By:		/s/ Michael Boggs
Name:		Michael Boggs
Title:		Managing Member

REVELATION HEALTHCARE FUND II, LLC

By:		/s/ Michael Boggs
Name:		Michael Boggs
Title:		Managing Member